Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Adenocarcinoma Of Esophagus × tucatinib × Clear all

Phase

Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

HER2-positive Breast Cancer 1 Adenocarcinoma Of Esophagus 1

Interventions

Nivolumab 3 Ramucirumab 2 Radiotherapy 2 Paclitaxel 2 Cisplatin 2 Capecitabine 2 tucatinib 1 Trastuzumab 1 Taxes 1 Specimen Handling 1 Oxaliplatin 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Folfox protocol 1 Fluorouracil 1 Drug Therapy 1 Cetuximab 1 CP protocol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04499924 2025-01-22

MOUNTAINEER-02

Seagen Inc.

Phase 2/3 Completed

17 enrolled 23 charts

Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon ⚡